Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168298 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 668
- Enrollment target
NCT00168298 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 668 participants.
The verdict
NCT00168298, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 668 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
Interventions
- OTHER Sham Injection
- DRUG 700 µg Dexamethasone
- DRUG 350 µg Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 668 participants |
| Start Date | 2004-11-01 |
| Est. Completion | 2008-09-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168298
The ClinicalTrials.gov registry entry for NCT00168298 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 668 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Injection is the first listed.
NCT00168298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168298 about?
NCT00168298 is a clinical study titled "A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion". This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
What is the current status of trial NCT00168298?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 668 participants. The study started on 2004-11-01. Estimated completion is 2008-09-05.
What interventions are being tested in trial NCT00168298?
The interventions under investigation include: Sham Injection (OTHER), 700 µg Dexamethasone (DRUG), 350 µg Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00168298?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.